## JOURNAL ARTICLES AND FEDERAL REGISTER NOTICES

Article, "Use, Misuse and Abuse of Amphetamine-type Drugs from the Medical Viewpoint," by Maurice Seevers, Ph. D., M.D., Department of Pharmacology, University of Michigan Medical School, Ann Arbor,	
Mich., from the National Institute on Amphetamine Abuse, Edwards- ville, Ill., 1966	Page 15089
M.D., Salt Lake City, Utah, from the Annals of Internal Medicine, 74-605-610, 1971, pp. 605-610	15097
1972	15103
Article, "Amphetamines: Tighter Controls on the Horizon," by Constance Holden, from the Science, vol. 194, pp. 1027-28, Dec. 3, 1976Notice, "Certain Anorectic Drugs—Drugs for Human Use; Drug Efficacy Study Implementation," Food and Drug Administration, Department of Health, Education, and Welfare, from the Federal Register, vol. 35,	15106
No. 154, Aug. 8, 1970, pp. 12678-79.  Rules and regulations, "Title 21—Food and Drugs, Part 130—New Drugs," Food and Drug Administration, Department of Health, Education, and Welfare, from the Federal Register, vol. 35, No. 154, Aug. 8, 1970, pp.	15108
12652-53 Rules and regulations, "Title 21—Food and Drugs, Part 130—New Drugs, Amphetamines for Human Use." Food and Drug Administration.	15111
Department of Health, Education, and Welfare, from the Federal Register, vol. 38, No. 28, Feb. 12, 1973, pp. 4249-50	15113
Notice "Amphetemines for Human Use—Notice of Withdrawal of Ap-	15116
proval of New Drug Applications," Food and Drug Administration, Department of Health, Education, and Welfare, from the Federal Register, vol. 38, No. 61, Mar. 30, 1973, pp. 8240-41	15123
Health, Education, and Welfare, from the Federal Register, vol. 38, No. 185, Sept. 25, 1973	15126
trolled Release Dosage Forms," from the Federal Register, vol. 39, No. 140, July 19, 1974, pp. 26459-62  Notice, "Bamadex Sequels—Denial of Hearing and Withdrawal of Approval of New Drug Application," Food and Drug Administration, Department of Health, Education, and Welfare, from the Federal	15128
Register, vol. 40, No. 101, May 23, 1975, pp. 22570-75Momentum dated Feb. 20, 1973, through Director, Division of Neuro-	
pharmacological Drug Products, from Barrett Scovine, M.D	15143
DEPARTMENT OF JUSTICE, DRUG ENFORCEMENT AGENCY	
Memorandum dated Sept. 28, 1971, to Robert J. Rosthal, Acting Chief Counsel, from Kenneth A. Durrin, Chief, Compliance Investigations Divisions, Department of Justice	15146
Memorandum dated Oct. 8, 1971, to all domestic regional directors, from John R. Enright, Chief of Operations, Department of Justice	15148
from Kenneth A. Durrin, Chief, Compliance Investigations Division, Department of Justice Memorandum dated Nov. 22, 1971, to Hon. John N. Mitchell, Attorney	15154
General, from John E. Ingersoll, Director, Bureau of Narcotics and Dangerous Drugs, Department of Justice  Memorandum undated, to Andrew C. Tartaglino, Deputy Director for	15157
Operations, from Kenneth A. Durrin, Assistant Director for Compliance, Department of Justice	15159